VS

Venkata Subrahmanyam Chittala

Active Director Director DIN 06671421
DIN 06671421 First appointment Sep 2013 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Sep 2013
Shareholding value •••• Premium profile

About Venkata Subrahmanyam Chittala

Data last updated:

Venkata Subrahmanyam Chittala is a Director at Atmus Pharma Private Limited (since 2022), Director at Jsl Health Sciences Private Limited (since 2020) and Director at Cenote Healthcare Private Limited (since 2022), and holds 1 more current directorship. The companies operate in Pharma, Food And Beverages and Construction. The 3 current companies with reported revenue have a combined latest revenue of ₹19.99 Cr; the largest is Atmus Pharma Private Limited at ₹16.50 Cr (FY 2025). Earlier, Venkata Subrahmanyam Chittala was a Director at Knbc Pharma Solutions Private Limited (2013–2015).

DIN 06671421
Primary Designation Director
Industry Pharma
First Appointment 13 Sep 2013
Oldest Company Age 6 yrs
Largest company Atmus Pharma Private Limited · ₹16.50 Cr (FY 2025)
Combined revenue ₹19.99 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Atmus Pharma Private Limited U24304TG2022PTC158653
Director10 Jan 20222022₹16.50 Cr (FY 2025)Active
Jsl Health Sciences Private Limited U24110TG2020PTC142645
Director08 Aug 20202020₹2.05 Cr (FY 2024)Active
Cenote Healthcare Private Limited U24304TG2022PTC158652
Director10 Jan 20222022₹1.43 Cr (FY 2025)Active
Designated Partner03 Aug 20222022Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director13 Sep 20132013₹6.2 Lakh (FY 2018)Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Jsl Health Sciences Private Limited
Cenote Healthcare Private Limited
Atmus Pharma Private Limited
Vertical Riser Projects Llp
Premium access

Shareholding and investment profile for Venkata Subrahmanyam Chittala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkata Subrahmanyam Chittala

Venkata Subrahmanyam Chittala currently holds 4 directorships: Atmus Pharma Private Limited (Director, since 10 Jan 2022, revenue ₹16.50 Cr (FY 2025)); Jsl Health Sciences Private Limited (Director, since 08 Aug 2020, revenue ₹2.05 Cr (FY 2024)); Cenote Healthcare Private Limited (Director, since 10 Jan 2022, revenue ₹1.43 Cr (FY 2025)); Vertical Riser Projects Llp (Designated Partner, since 03 Aug 2022).

Venkata Subrahmanyam Chittala was first appointed on 13 Sep 2013 as Director at Knbc Pharma Solutions Private Limited. The most recent appointment on record is 03 Aug 2022 at Vertical Riser Projects Llp.

The 3 current companies of Venkata Subrahmanyam Chittala that report revenue have a combined latest revenue of ₹19.99 Cr: Atmus Pharma Private Limited ₹16.50 Cr (FY 2025); Jsl Health Sciences Private Limited ₹2.05 Cr (FY 2024); Cenote Healthcare Private Limited ₹1.43 Cr (FY 2025).

Venkata Subrahmanyam Chittala held 1 earlier board appointment: Knbc Pharma Solutions Private Limited (Director, 13 Sep 2013 to 16 Apr 2015).

The current boards of Venkata Subrahmanyam Chittala's companies include Machara Lakshmi Chittala (Atmus Pharma Private Limited), Appala Ramaprasad Lanka (Jsl Health Sciences Private Limited), Adinagamani Lakku (Vertical Riser Projects Llp), Kishore Kumar Manem (Vertical Riser Projects Llp), Srirama Siva Prasada Rao Juluri (Vertical Riser Projects Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available